Systematic therapy for unresectable or metastatic soft-tissue sarcomas

Past, present, and future

Sherif S. Morgan, Lee D Cranmer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.

Original languageEnglish (US)
Pages (from-to)331-349
Number of pages19
JournalCurrent Oncology Reports
Volume13
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Sarcoma
Doxorubicin
Therapeutics
Cytotoxins
Drug Therapy

Keywords

  • Chemotherapy
  • Metastatic soft-tissue sarcoma
  • Sarcoma
  • Systemic therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Systematic therapy for unresectable or metastatic soft-tissue sarcomas : Past, present, and future. / Morgan, Sherif S.; Cranmer, Lee D.

In: Current Oncology Reports, Vol. 13, No. 4, 08.2011, p. 331-349.

Research output: Contribution to journalArticle

@article{c7af23914bb24fb08aa4602b00ddf52e,
title = "Systematic therapy for unresectable or metastatic soft-tissue sarcomas: Past, present, and future",
abstract = "Unresectable or metastatic disease occurs in 40{\%} to 60{\%} of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26{\%}. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.",
keywords = "Chemotherapy, Metastatic soft-tissue sarcoma, Sarcoma, Systemic therapy, Targeted therapy",
author = "Morgan, {Sherif S.} and Cranmer, {Lee D}",
year = "2011",
month = "8",
doi = "10.1007/s11912-011-0182-z",
language = "English (US)",
volume = "13",
pages = "331--349",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Systematic therapy for unresectable or metastatic soft-tissue sarcomas

T2 - Past, present, and future

AU - Morgan, Sherif S.

AU - Cranmer, Lee D

PY - 2011/8

Y1 - 2011/8

N2 - Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.

AB - Unresectable or metastatic disease occurs in 40% to 60% of soft-tissue sarcoma (STS) patients and portends a poor prognosis. For decades, doxorubicin has formed the backbone of systemic treatment, with response rates of approximately 26%. Patients progressing following first-line therapy were left with few proven options. No other cytotoxic chemotherapy agent or combination has demonstrated superiority to doxorubicin. Advances in targeted therapy of STS have been hindered by STS heterogeneity and poorly understood disease biology. Despite challenges, progress has been made in specific STS subtypes. Here, we highlight the challenges, progress, and lessons learned from STS trials published in the last 20 to 25 years.

KW - Chemotherapy

KW - Metastatic soft-tissue sarcoma

KW - Sarcoma

KW - Systemic therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80051665370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051665370&partnerID=8YFLogxK

U2 - 10.1007/s11912-011-0182-z

DO - 10.1007/s11912-011-0182-z

M3 - Article

VL - 13

SP - 331

EP - 349

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -